Nikhil Aneja was named Principal Accounting Officer of Aligos Therapeutics, Inc. As of November 14, 2026, Aligos Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 4, 2026, naming 1 appointment (Form 8-K, February 4, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Aligos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Aligos Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-04. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Aligos Therapeutics, Inc. files it.
Also on the record for Aligos Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G, by Parkman Healthcare Partners LLC | 5.2% of the class | 5%+ stakes | Source |
| June 24, 2026 | Stake report, Schedule 13D, by Lawrence M. Blatt | 5.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Lawrence M. Blatt | 5.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 4.4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 5.4% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Sio Capital Management, LLC | 5.46% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Woodline Partners LP | 8.7% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Woodline Partners LP | 9.8% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G, by Sio Capital Management, LLC | 5.49% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 3.9% of the class | 5%+ stakes | Source |
| February 28, 2025 | Form D, private offering | $105M sold | Form D page | Source |
Selling to them or working with them? See who runs Aligos Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aligos Therapeutics, Inc. and the records around it.
Aligos Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Parkman Healthcare Partners LLC also filed stake reports on 1 other company: InspireMD, Inc. (Nov 2025)
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
Watch Aligos Therapeutics, Inc.
Get an email when Aligos Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aligos Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aligos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aligos Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-04 | In | Principal Accounting Officer | 8-K, 2026-02-04 |
Who leads Aligos Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Principal Accounting Officer: Nikhil Aneja, appointed (filed 2026-02-04).
New leaders reset buying decisions — get the Full Report on Aligos Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Principal Accounting Officer at Aligos Therapeutics, Inc., with the record behind each one.
Find candidates like Principal Accounting Officer at Aligos Therapeutics, Inc.Every change, in the filing's words
Appointed: Nikhil Aneja, Principal Accounting Officer
On January 29, 2026, the Board of Directors of Aligos Therapeutics, Inc. (the "Company") appointed Nikhil Aneja as the Company's Principal Accounting Officer, effective immediately.
- In this role, Mr. Aneja succeeds Lesley Ann Calhoun, who continues to serve as the Company's Executive Vice President, Chief Operating Officer & Chief Financial Officer.
- Mr. Aneja, age 49, has served as the Company's Vice President, Finance since February 2024.
- From December 2022 to February 2024, Mr. Aneja served as Vice President, Corporate Controller at CareDx, Inc., a diagnostic company.
- Prior to that, Mr. Aneja served as Vice President, Finance and Accounting at Blade Therapeutics, Inc., a biopharmaceutical company, from May 2021 to October 2022, and as Executive Director, Global Corporate Controller at Global Blood Therapeutics, Inc., a biopharmaceutical company, from September 2016 to May 2021.
- He received his Bachelor of Commerce from the University of Delhi and is a Certified Public Accountant.
Tools for this story
Each opens in a new tab, filled in for Aligos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
